Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks kidney drug use across eastern europe

NCT ID NCT06203704

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how doctors in seven Central Eastern European countries prescribe dapagliflozin for chronic kidney disease in routine care. Researchers reviewed medical records of about 1,090 adults to understand who gets the drug and what happens over the next year. The goal was to gather real-world insights, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,086 people

The number who actually took part.

Started

Dec 2023

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adult patients with CKD who meet the country-specific label for dapagliflozin as treatment for CKD across CEE. Patients newly initiated on treatment with dapagliflozin for CKD will be eligible for enrolment by physicians from both outpatient and inpatient settings.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients (age ≥18 years) at the time of dapagliflozin start 2. Patient receives treatment with dapagliflozin for CKD in accordance with the dapagliflozin product label and local dapagliflozin reimbursement criteria for CKD Note: CKD diagnosis is based on the following KDIGO criteria \[KDIGO 2012\] that defines CKD as abnormalities of kidney structure or function, present for \>3 months, with implications for health and at least one of the following criteria: * AER ≥30 mg/24 hours; * ACR ≥30 mg/g (≥3 mg/mmol); * eGFR \<60 ml/min/1.73 m2. 3. Signed and dated informed consent prior to enrollment in the study. Exclusion Criteria: 1. Diagnosed with type 1 diabetes \[ICD-10 codes E10 and O24.0\] at any time before index date. 2. Diagnosed with gestational diabetes mellitus \[ICD-10 code O24.419\] at any time before index date. 3. Patient is enrolled less than 30 days or more than 90 days, following initiation of dapagliflozin. 4. Prior treatment (at any time before index date) with dapagliflozin or other SGLT-2i 5. Enrolment in a clinical trial that includes specific treatments as investigational medicinal product on or 3 months before index date 6. Renal transplant at any time before index date 7. End stage renal disease (eGFR \<15 ml/min/1.73m2) on index date 8. Chronic dialysis on or at any time before index date

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease (CKD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease (CKD)

Contacts and locations

Locations

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Varna, Bulgaria

  • Research Site

    Zagreb, Croatia

  • Research Site

    Békéscsaba, Hungary

  • Research Site

    Budapest, Hungary

  • Research Site

    Debrecen, Hungary

  • Research Site

    Gödöllő, Hungary

  • Research Site

    Karcag, Hungary

  • Research Site

    Kecskemét, Hungary

  • Research Site

    Miskolc, Hungary

  • Research Site

    Nagykanizsa, Hungary

  • Research Site

    Nyíregyháza, Hungary

  • Research Site

    Pécs, Hungary

  • Research Site

    Siófok, Hungary

  • Research Site

    Szeged, Hungary

  • Research Site

    Szombathely, Hungary

  • Research Site

    Veszprém, Hungary

  • Research Site

    Bialystok, Poland

  • Research Site

    Bolesławiec, Poland

  • Research Site

    Bydgoszcz, Poland

  • Research Site

    Choszczno, Poland

  • Research Site

    Czarnków, Poland

  • Research Site

    Katowice, Poland

  • Research Site

    Krakow, Poland

  • Research Site

    Lodz, Poland

  • Research Site

    Olsztyn, Poland

  • Research Site

    Opole, Poland

  • Research Site

    Sieradz, Poland

  • Research Site

    Szczecin, Poland

  • Research Site

    Środa Wielkopolska, Poland

  • Research Site

    Węgrów, Poland

  • Research Site

    Wroclaw, Poland

  • Research Site

    Zielona Góra, Poland

  • Research Site

    Żywiec, Poland

  • Research Site

    Bistriţa, Romania

  • Research Site

    Bucharest, Romania

  • Research Site

    Cluj-Napoca, Romania

  • Research Site

    Galati, Romania

  • Research Site

    Iași, Romania

  • Research Site

    Oradea, Romania

  • Research Site

    Reşiţa, Romania

  • Research Site

    Satu Mare, Romania

  • Research Site

    Târgu Mureş, Romania

  • Research Site

    Timișoara, Romania

  • Research Site

    Belgrade, Serbia

  • Research Site

    Brežice, Slovenia

  • Research Site

    Cerknica, Slovenia

  • Research Site

    Menges, Slovenia

  • Research Site

    Portorož, Slovenia

  • Research Site

    Ptuj, Slovenia

  • Research Site

    Radlje ob Dravi, Slovenia

  • Research Site

    Ruše, Slovenia

  • Research Site

    Sevnica, Slovenia

  • Research Site

    Škofja Loka, Slovenia

  • Research Site

    Zagorje, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.